Improved lipid-lowering treatment and reduction in cardiovascular disease burden in homozygous familial hypercholesterolemia: The SAFEHEART follow-up study.

doi:10.1016/j.atherosclerosis.2024.117516

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Improved lipid-lowering treatment and reduction in cardiovascular disease burden in homozygous familial hypercholesterolemia: The SAFEHEART follow-up study.

Atherosclerosis - 1 Jun 2024

Alonso Rodrigo, Arroyo-Olivares Raquel, Díaz-Díaz Jose Luis, Fuentes-Jiménez Francisco, Arrieta Francisco, de Andrés Raimundo, Gonzalez-Bustos Pablo, Argueso Rosa, Martin-Ordiales Mercedes, Martinez-Faedo Ceferino, Illán Fátima, Saenz Pedro, Donate José María, Sanchez Muñoz-Torrero Juan F, Martinez-Hervas Sergio, Mata Pedro

Abstract excerpt

AIM: We aimed to describe clinical and genetic characteristics, lipid-lowering treatment and atherosclerotic cardiovascular disease (ASCVD) outcomes over a long-term follow-up in homozygous familial hypercholesterolemia (HoFH). METHODS: SAFEHEART (Spanish Familial Hypercholesterolaemia Cohort Study) is a long-term study in molecularly diagnosed FH. Data analyzed in HoFH were prospectively obtained from 2004 until...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticholesteremic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cholesterol, LDL

Share to Ezetimibe

Share to Follow-Up Studies

Share to Hydroxymethylglutaryl-CoA Reductase Inhibitors

Share to Hyperlipoproteinemia Type II

Share to Proprotein Convertase 9

Share to Spain

Source

Open in PubMed

Identifiers

PMID: 38523000
DOI: 10.1016/j.atherosclerosis.2024.117516

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Improved lipid-lowering treatment and reduction in cardiovascular disease burden in homozygous familial hypercholesterolemia: The SAFEHEART follow-up study.PMID 38523000Read ↗

Clinical characteristics and lipid management of patients with familial hypercholesterolemia: results from a 7 years single-centre experience.Semantic proximity Read ↗

Clinical and molecular characteristics of homozygous familial hypercholesterolemia patients: Insights from SAFEHEART registry.Semantic proximity Read ↗

Mutational analysis and genotype-phenotype relation in familial hypercholesterolemia: The SAFEHEART registry.Semantic proximity Read ↗

Homozygous familial hypercholesterolemia (HoFH) in Canada.Semantic proximity Read ↗

Improved cardiovascular outcomes following temporal advances in lipid-lowering therapy in a genetically-characterised cohort of familial hypercholesterolaemia homozygotes.Semantic proximity Read ↗

Long-term outcome in 53 patients with homozygous familial hypercholesterolaemia in a single centre in France.Semantic proximity Read ↗

Consensus document on diagnosis and management of familial hypercholesterolemia from the Italian Society for the Study of Atherosclerosis (SISA).Semantic proximity Read ↗

Contemporary lipid-lowering management and risk of cardiovascular events in homozygous familial hypercholesterolaemia: insights from the Italian LIPIGEN Registry.Semantic proximity Read ↗

Management and Consequences of Genotype-Positive Familial Hypercholesterolemia.Semantic proximity Read ↗

Homozygous familial hypercholesterolemia in China: Genetic and clinical characteristics from a real-world, multi-center, cohort study.Semantic proximity Read ↗

Why patients with familial hypercholesterolemia are at high cardiovascular risk? Beyond LDL-C levels.Semantic proximity Read ↗

Incidence of Cardiovascular Disease in Patients with Familial Hypercholesterolemia Phenotype: Analysis of 5 Years Follow-Up of Real-World Data from More than 1.5 Million PatientsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.